BioSpace News Archive

Complete Response Letter Requests Additional Chemistry Manufacturing and Controls (CMC) and Non-Clinical Information

Athira Pharma, Inc., a clinical-stage company dedicated to developing first-in-class therapies for Alzheimer’s and Parkinson’s that are focused on regeneration, today announced the appointment of Hans J. Moebius, MD, PhD, ECPM, FAAN, as Chief Medical Officer to support the company’s therapeutic development efforts.

Aurora BioSolutions Inc. and Tissue Regeneration Therapeutics Inc. announce they have discovered that human umbilical cord cells are a sustainable source of human butyrylcholinesterase, a bioscavenger that neutralizes organophosphate nerve toxins.

New World Medical, Inc., a privately held ophthalmic company dedicated to developing cutting-edge glaucoma medical devices intended to alleviate the suffering of patients globally, is pleased to announce the recipients of its annual Humanitarian Project Award, Health Outcomes Research Award, and Fellowship Awards.

Sotera Wireless, maker of the ViSi Mobile® Surveillance Monitoring System will be exhibiting at the Institute for Healthcare Improvement Patient Safety Congress (IHI) on May 15-17 in Houston, TX

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it has signed an agreement with NeuroMuscular Orthotics Pty Ltd (NMO) with the goal of offering MyoPro across Australia and New Zealand.

Noble unveiled a new injection training platform based on 1 mL and 2.25 mL YpsoMate devices to help improve patient onboarding and health outcomes.

Officials from Health Canada will hold a technical briefing to provide information on the final publication of the Tobacco Products Regulations.

Dr. Mark McClellan, Manik Bhat, Tim Petrikin, and Adam Kaufman have joined HT4M’s Board of Directors.

Sigilon Therapeutics delivered an oral presentation featuring data on its hemophilia A program at the American Society of Gene and Cell Therapy Annual Meeting in Washington, D.C. The data presented will support the company’s planned regulatory filing of SIG-001 later this year to enable initiation of clinical trials.